Literature DB >> 1882507

Protection against murine potomac horse fever by an inactivated Ehrlichia risticii vaccine.

Y Rikihisa1.   

Abstract

Ehrlichia risticii propagated in a murine macrophage cell line were freed from the host cell by hypotonic lysis of the infected cells. The cell-free ehrlichiae were inactivated with beta-propiolactone and combined or not combined with polymyxin-B. The vaccines were administered to mice with Quil-A (saponin) as an adjuvant twice at 2 to 3 week intervals and the mice were challenged with live E. risticii 2 to 3 weeks after the last vaccination. With or without the addition of polymyxin-B, the vaccine preparations protected mice from developing clinical signs and gross pathologic changes such as thymic atrophy, splenomegaly, and increase in whole intestinal weight. Mice vaccinated with or without polymyxin-B developed high titer IgG antibody against E. risticii before and after the challenge with live E. risticii. Spleen lymphocyte proliferative response assay at 11 days post challenge revealed that with polymyxin-B a higher lymphocyte proliferation occurred as compared with that of the mice which received polymyxin-B-free vaccine. Spleen lymphocytes of the placebo (polymyxin-B and Quil-A) pretreated/challenged mice showed no proliferative activity. Western blot analysis revealed that vaccinated mice reacted mainly with 110, 57 and 33 kDa antigen bands before and after challenge. The placebo (polymyxin-B and Quil-A)/challenged mice showed a very weak response to ehrlichial antigens at day 10 to 11 post challenge. Comparison with inactivated Renografin-purified E. risticii or 0.25% SDS-insoluble fraction of E. risticii with the inactivated host cell-free vaccine revealed no increased protection. These results indicate that inactivated host cell-free E. risticii can protect mice from murine Potomac horse fever. The presence of polymyxin-B appeared to be not harmful but rather beneficial for lymphocyte proliferation response upon challenge with live E. risticii.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1882507     DOI: 10.1016/0378-1135(91)90159-d

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Analysis of 16S rRNA and 51-kilodalton antigen gene and transmission in mice of Ehrlichia risticii in virgulate trematodes from Elimia livescens snails in Ohio.

Authors:  M Kanter; J Mott; N Ohashi; B Fried; S Reed; Y C Lin; Y Rikihisa
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

2.  Inhibition of binding, entry, or intracellular proliferation of Ehrlichia risticii in P388D1 cells by anti-E. risticii serum, immunoglobulin G, or Fab fragment.

Authors:  J B Messick; Y Rikihisa
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

3.  Tumor necrosis factor alpha, interleukin-1 alpha, interleukin-6, and prostaglandin E2 production in murine peritoneal macrophages infected with Ehrlichia risticii.

Authors:  A M van Heeckeren; Y Rikihisa; J Park; R Fertel
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

4.  Analysis of complete genome sequence of Neorickettsia risticii: causative agent of Potomac horse fever.

Authors:  Mingqun Lin; Chunbin Zhang; Kathryn Gibson; Yasuko Rikihisa
Journal:  Nucleic Acids Res       Date:  2009-08-06       Impact factor: 16.971

5.  Antigenic, morphologic, and molecular characterization of new Ehrlichia risticii isolates.

Authors:  W Chaichanasiriwithaya; Y Rikihisa; S Yamamoto; S Reed; T B Crawford; L E Perryman; G H Palmer
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

6.  Neorickettsia risticii surface-exposed proteins: proteomics identification, recognition by naturally-infected horses, and strain variations.

Authors:  Kathryn E Gibson; Gabrielle Pastenkos; Susanne Moesta; Yasuko Rikihisa
Journal:  Vet Res       Date:  2011-06-02       Impact factor: 3.683

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.